For the first time in many years, the ADA has updated their guidelines on retinopathy. These new guidelines take into account the improvements that have been made in diagnosis and both medical and physical treatments. Most of our colleagues at other medical news outlets either paraphrased the guidelines or printed …

Improvements in assessment and treatment of diabetic retinopathy position statement

This represents the first such update by the American Diabetes Association since 2002, and is notable for inclusion of the latest evidence and recommendations with respect to appropriate eye examination intervals, referral criteria, prevention of incidence and progression of diabetic retinopathy (DR), and treatment strategies.

Should metformin or glyburide, or a combination of both drugs, be the first-line treatment for gestational diabetes?

Is innovative telemedicine the answer to preventing and treating diabetes?

Can patients who use insulin safely fast?

To fast or not to fast.

When asked in a survey, 77% got it wrong! In head-to-head trials of dipeptidyl peptidase 4 (DPP-4) inhibitors vs glucagon-like peptide 1 (GLP-1) receptor agonists, GLP-1 receptor agonists showed more favorable outcomes in all of the following areas except which one? A. Greater glycemic control B. Greater tolerability C. Greater weight loss D. Greater improvement in beta-cell function E. Greater reduction in postprandial triglycerides Were you able to get it right? Follow the link to find out!

Now that a new combination drug of a GLP-1 plus DPP-4 is approved, will you: 1. Recommend it for current patients 2. Wait until we have further information on its use 3. Not sure Follow the link to respond and see what your colleagues think.

Developed by diabetics for diabetics. DiabetesPlus lets you administer your readings on your device and saves time by enabling you to send the data directly to your doctor.